PT2768796T - Processo para a preparação de derivados de quinolina - Google Patents

Processo para a preparação de derivados de quinolina

Info

Publication number
PT2768796T
PT2768796T PT127837631T PT12783763T PT2768796T PT 2768796 T PT2768796 T PT 2768796T PT 127837631 T PT127837631 T PT 127837631T PT 12783763 T PT12783763 T PT 12783763T PT 2768796 T PT2768796 T PT 2768796T
Authority
PT
Portugal
Prior art keywords
quinoline derivatives
preparing quinoline
preparing
derivatives
quinoline
Prior art date
Application number
PT127837631T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PT2768796T publication Critical patent/PT2768796T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT127837631T 2011-10-20 2012-10-22 Processo para a preparação de derivados de quinolina PT2768796T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161549312P 2011-10-20 2011-10-20

Publications (1)

Publication Number Publication Date
PT2768796T true PT2768796T (pt) 2020-02-21

Family

ID=47146705

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127837631T PT2768796T (pt) 2011-10-20 2012-10-22 Processo para a preparação de derivados de quinolina

Country Status (23)

Country Link
US (3) US9365516B2 (enExample)
EP (1) EP2768796B1 (enExample)
JP (2) JP6208140B2 (enExample)
KR (1) KR102075371B1 (enExample)
CN (2) CN110511158A (enExample)
AR (1) AR088483A1 (enExample)
AU (2) AU2012325768B2 (enExample)
BR (1) BR112014009302B1 (enExample)
CA (1) CA2852771C (enExample)
DK (1) DK2768796T3 (enExample)
EA (1) EA031485B1 (enExample)
ES (1) ES2765013T3 (enExample)
GE (1) GEP20207110B (enExample)
HU (1) HUE048023T2 (enExample)
IL (1) IL232139A (enExample)
IN (1) IN2014CN02971A (enExample)
MX (1) MX343288B (enExample)
PL (1) PL2768796T3 (enExample)
PT (1) PT2768796T (enExample)
TW (2) TWI642650B (enExample)
UA (1) UA116876C2 (enExample)
WO (1) WO2013059788A1 (enExample)
ZA (1) ZA201402579B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057184T2 (hu) 2010-07-16 2022-04-28 Exelixis Inc C-MET modulátor gyógyszerészeti készítmények
CN103402505A (zh) 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
KR102030447B1 (ko) 2011-02-10 2019-11-08 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
IN2014CN02971A (enExample) * 2011-10-20 2015-07-03 Exelixis Inc
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス, インク. 溶骨性骨転移を治療するためのmet−vegf二重調節剤
EP2970126B1 (en) 2013-03-15 2019-03-06 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
WO2014165786A1 (en) 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
CN104649969B (zh) * 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
AU2015218236B2 (en) 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス, インコーポレイテッド カボザンチニブ製剤の投与
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
WO2016019285A1 (en) 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
KR102634247B1 (ko) 2014-08-05 2024-02-05 엑셀리시스, 인코포레이티드 다발성 골수종을 치료하기 위한 약물 병용물
US10745346B2 (en) * 2015-09-02 2020-08-18 Kuen-Feng Chen Agonists of protein tyrosine phosphatase SHP-1
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN109836382B (zh) * 2017-11-29 2021-11-05 江苏豪森药业集团有限公司 苹果酸卡博替尼及其中间体的制备方法
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
US12497367B2 (en) 2020-04-30 2025-12-16 Exelixis, Inc. Processes for the preparation of a kinase inhibitor
CN112142619B (zh) * 2020-10-20 2023-01-10 浙江工业大学 一种1,1-环丙烷二羧酸酰胺类化合物及其制备方法和应用
US20240190825A1 (en) * 2021-03-24 2024-06-13 Biocon Limited Process for preparation of cabozantinib
AU2023384196A1 (en) * 2022-11-25 2025-06-12 Msn Laboratories Private Limited, R&D Center Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2392565B1 (en) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
CA2603748A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
AU2007334402B2 (en) 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
US8445509B2 (en) * 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
AR075084A1 (es) * 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
NZ592827A (en) * 2008-11-13 2013-06-28 Exelixis Inc Methods of preparing quinoline derivatives
JP2012511017A (ja) 2008-12-04 2012-05-17 エグゼリクシス, インコーポレイテッド キノリン誘導体の調製方法
PT2387563E (pt) 2009-01-16 2013-03-25 Exelixis Inc Sal de malato de n-(4-{[6,7-bis(metiloxi)quinolin-4- il]oxi}fenil)-n¿-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, e suas formas cristalinas para o tratamento de cancro
KR20120051702A (ko) 2009-07-17 2012-05-22 엑셀리시스, 인코포레이티드 N-〔3-플루오로-4-({6-(메틸옥시)-7-〔(3-모르폴린-4-일프로필)옥시〕퀴놀린-4-일}옥시)페닐〕-n''-(4-플루오로페닐)시클로프로판-1,1-디카르복사미드의 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
SG184040A1 (en) 2010-03-12 2012-10-30 Exelixis Inc Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
US20140186407A9 (en) 2010-07-16 2014-07-03 Exelixis Inc. C-Met Modulator Pharmaceutical Compositions
HUE057184T2 (hu) 2010-07-16 2022-04-28 Exelixis Inc C-MET modulátor gyógyszerészeti készítmények
CN103402505A (zh) 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
CA2812753A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
JP2013537918A (ja) 2010-09-27 2013-10-07 エクセリクシス, インク. 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのmetおよびvegfの二元阻害薬
WO2012071321A1 (en) 2010-11-22 2012-05-31 Glaxosmithkline Llc Method of treating cancer
KR102030447B1 (ko) 2011-02-10 2019-11-08 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
IN2014CN02971A (enExample) * 2011-10-20 2015-07-03 Exelixis Inc
KR20140088610A (ko) 2011-11-08 2014-07-10 엑셀리시스, 인코포레이티드 암을 치료하기 위한 met 및 vegf의 이중 저해제
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス, インク. 溶骨性骨転移を治療するためのmet−vegf二重調節剤
WO2014039971A1 (en) 2012-09-07 2014-03-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma

Also Published As

Publication number Publication date
BR112014009302A2 (pt) 2017-05-23
HUE048023T2 (hu) 2020-05-28
BR112014009302B1 (pt) 2020-04-28
CA2852771C (en) 2019-11-26
EA201490831A1 (ru) 2014-09-30
EP2768796B1 (en) 2019-11-20
CA2852771A1 (en) 2013-04-25
PL2768796T3 (pl) 2020-05-18
TWI619694B (zh) 2018-04-01
KR20140088874A (ko) 2014-07-11
KR102075371B1 (ko) 2020-02-10
CN104395284A (zh) 2015-03-04
EP2768796A1 (en) 2014-08-27
AU2012325768A1 (en) 2014-05-22
ES2765013T3 (es) 2020-06-05
HK1201517A1 (en) 2015-09-04
TW201321342A (zh) 2013-06-01
DK2768796T3 (da) 2020-02-24
UA116876C2 (uk) 2018-05-25
JP2014530880A (ja) 2014-11-20
TWI642650B (zh) 2018-12-01
JP2017222648A (ja) 2017-12-21
IL232139A (en) 2017-11-30
US20140256938A1 (en) 2014-09-11
NZ723880A (en) 2018-03-23
JP6208140B2 (ja) 2017-10-04
AU2012325768B2 (en) 2017-08-10
AU2017254982A1 (en) 2017-11-23
WO2013059788A1 (en) 2013-04-25
AR088483A1 (es) 2014-06-11
US9969692B2 (en) 2018-05-15
US20180230100A1 (en) 2018-08-16
EA031485B1 (ru) 2019-01-31
US20160229805A1 (en) 2016-08-11
MX343288B (es) 2016-11-01
ZA201402579B (en) 2015-03-25
GEP20207110B (en) 2020-05-25
MX2014004583A (es) 2014-10-06
US9365516B2 (en) 2016-06-14
NZ624328A (en) 2016-10-28
TW201731812A (zh) 2017-09-16
IN2014CN02971A (enExample) 2015-07-03
IL232139A0 (en) 2014-05-28
GEAP201913471A (en) 2019-10-25
CN110511158A (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
IL232139A0 (en) A process for the preparation of quinoline hist
IL238454B (en) A process for the preparation of bile acid derivatives
ZA201304330B (en) Method for preparing 2-aminobenzamide derivatives
IL222290A0 (en) Process for preparing aminobenzofuran derivatives
IL222191A0 (en) Process for preparing sulfonamido-benzofuran derivatives
IL230594A0 (en) Process for the preparation of nitrogen-substituted 1h-pyrazole-5-carbonyl chloride compounds
IL227646A0 (en) Process for preparing 4-amino-3-chloro-5-fluoro-6-(converted) picolinates
ZA201305582B (en) Process for the preparation of 4-amino-5-fluoro-3-halo-6-(sunstituted)picolinates
IL227872A0 (en) A process for the preparation of n-converted phenylhydroxylamines
ZA201207386B (en) Process for preparing benzoxaboroles
ZA201402624B (en) Process for preparing buprenorphine
IL227645B (en) Process for preparing 4-amino-3-chloro-5-fluoro-6-(converted) picolinates
IL227220A (en) A process for preparing a history of 3-alkylsulfinylbenzoyl
SG11201401572SA (en) Processes for preparing indoles
SI2753620T1 (sl) Novi postopek za pripravo fosamilceftarolina
EP2619174A4 (en) PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES
PL2940000T3 (pl) Sposób wytwarzania octanu metylu
IL223145A0 (en) Process for preparing dithiine-tetracarboxy-diimides
ZA201207819B (en) Oxidation process for preparing 3-formyl-cephem derivatives
EP2662376A4 (en) PROCESS FOR THE PRODUCTION OF TORISEL
IL235300A0 (en) A process for the preparation of naphthyridine hist
IL238934A (en) Methods for making phenyloxymethyl-nitro-imidazole derivatives